A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 1, 1998, Pages 11-25

  Karlsson, Mats O ^a   Molnar, Valeria ^b   Bergh, Jonas ^b   Freijs, Agneta ^b   Larsson, Rolf ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER SIMULATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; HYPOTHESIS; INTERMETHOD COMPARISON; LEUKOPENIA; MODEL; ORAL DRUG ADMINISTRATION; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BONE MARROW; BREAST NEOPLASMS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKOCYTE COUNT; MODELS, THEORETICAL; NEUTROPENIA; NEUTROPHILS; OVARIAN NEOPLASMS; PACLITAXEL; PHARMACOKINETICS; TIME FACTORS;

EID: 0031940674     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90117-5     Document Type: Article

References (20)

1. Jakobsen P, Bastholt L, Dalmark M, Pfeifer P, Petersen D, Gjedde SB, et al. A randomized study of epirubicin at four different dose levels in advanced breast cancer: feasibility of myelotoxicity prediction through single blood-sample measurement. Cancer Chemother Pharmacol 1991;28:465-9.
2. Calvert AH. Dose optimisation of carboplatin in adults. Anticancer Res 1994;14:2273-8.
3. Kearns CM, Gianni L, Egorin MJ. Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 1995;22(suppl 6):16-23.
4. Boven E, Schipper H, Erkelens CA, Hatty SA, Pinedo HM. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer 1993;68:52-6.
5. Ruiz van Haperen VW, Veerman G, Boven E, Noordhuis P, Vermerken JB, Peters GJ. Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidin (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol 1994;48:1327-39.
6. Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G, Peters GJ. Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol 1995;22:42-6.
7. Joel SP, Shah R, Slevin ML. Etoposide dosage and pharmacodynamics. Cancer Chemother Pharmacol 1994;34(suppl):S69-75.
8. Kaojarern S, Day B, Brater DC. The time-course of delivery of furosemide into urine: an independent determinant of overall response. Kidney Int 1982;22: 69-74.
9. Alvan G, Helleday L, Lindholm A, Sanz E, Villen T. Diuretic effect and diuretic efficiency after intravenous dosage of frusemide. Br J Clin Pharmacol 1990;29:215-9.
10. Rizzo J, Riley C, von Hoff D. Analysis of anticancer drugs in biological fluids: determination of taxol with application to clinical pharmacokinetics. J Pharm Biomed Anal 1990;8:159-64.
11. Beal SL, Sheiner LB, editors. NONMEM user's guides. San Francisco: NONMEM Project Group, University of California; 1992.
12. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13:180-90.
13. Karlsson MO, Port RE, Ratain MJ, Sheiner LB. A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther 1995;57:325-34.
14. Carrol RJ, Ruppert D. Transformation and weighting in regression. New York: Chapman and Hall; 1988.
15. Segre G. Kinetics of interaction between drugs and biological systems. Farmaco (Sci) 1968;23:907-18.
16. Sheiner LB, Stanski DR, Vozeh S, Miller RD. Simultaneous modeling of pharmacokinetics and pharmacodynamics application to D-tubocurarine. Clin Pharmacol Ther 1979;25:358-71.
17. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993;21:457-78.
18. Sheiner LB, Verotta D. Further notes on physiologic indirect response models [letter]. Clin Pharmacol Ther 1995;58:238-40.
19. Wagner JG. Kinetics of pharmacological response; I: proposed relationships between response and drug concentration in the intact animal and man. J Theor Biol 1968;20:173-201.
20. Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 1994;12:532-8.